But while the amount of active executive caspases continually increased in CML during the 48 h after drug addition, in PBL transient caspase 3 activation in 24 h was followed by subsequent decrease under the control level (data not shown). This evidence concerns the gene CASP3 and chronic myelogenous leukemia, BCR-ABL1 positive.